IDEXX Laboratories Launches the Diagnostic Health Profile for the VetTest® Chemistry Analyzer [Trade]

Westbrook, Maine, April 13, 2007—IDEXX Laboratories, Inc. (NASDAQ:IDXX), announces the launch of the Diagnostic Health Profile (DHP), a panel that provides 13 results and offers veterinarians a new choice in creating a minimum diagnostic database. The DHP runs on the IDEXX VetTest® Chemistry Analyzer in just minutes and offers more focused liver-testing capabilities and the ability to monitor pancreatic health.

The new DHP consists of tests for ALB, ALKP, ALT, AMYL, BUN, CA, CREA, GLU, GGT, LIPA, TBIL and TP, and provides a calculation for globulin. With both amylase and lipase, the profile can help practitioners detect pancreatitis and quickly begin treatment. GGT is included to better differentiate certain types of liver disease in cats, and to help rule out drug-related diagnoses in dogs, as it is less influenced by enzyme-inducing drugs.

“Our customers told us they would benefit from prepackaged panels that provide a more convenient way to monitor pancreatic health and differentiate cholestatic liver disease.” said Jennifer Mazjanis, LVT, Chemistry Marketing Manager. “For example, we discovered that practices often add lipase to the GHP in order to screen for pancreatitis, so lipase is a standard part of the new VetTest DHP. This new profile will help VetTest Analyzer users quickly assess the situation and begin targeting and treating the root cause of their patients’ distress immediately.”

The DHP offers a choice in testing for both healthy patients and those showing clinical signs. With the chemistries run on the VetTest Analyzer, doctors can rely on proven dry-slide technology—designed to minimize the effects of interferants and provide uncompromising accuracy—for trusted results. The VetTest Analyzer is an integral part of the IDEXX VetLab® Suite, trusted by more veterinarians worldwide as their in-house laboratory, delivering comprehensive and immediate information on blood chemistries, electrolytes, hematology, endocrinology, urinalysis and blood gases.

For more information, practitioners can contact their authorized IDEXX distributor representative, call IDEXX at 1-800-355-2896 or visit www.idexx.com/vettest.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and pharmaceuticals. IDEXX’s products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (623 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.